| アイテムタイプ |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2025-03-25 |
| タイトル |
|
|
タイトル |
Momelotinib versus ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis: an efficacy/safety analysis in the Japanese subgroup of the phase 3 randomized SIMPLIFY-1 trial |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
言語 |
en |
|
キーワード |
Japan |
| キーワード |
|
|
言語 |
en |
|
キーワード |
Momelotinib |
| キーワード |
|
|
言語 |
en |
|
キーワード |
Myelofibrosis |
| キーワード |
|
|
言語 |
en |
|
キーワード |
Phase 3 |
| キーワード |
|
|
言語 |
en |
|
キーワード |
Ruxolitinib |
| 資源タイプ |
|
|
資源タイプ |
journal article |
| アクセス権 |
|
|
アクセス権 |
open access |
| 著者 |
下田, 和哉
WEKO
7997
e-Rad_Researcher
90311844
| en |
Shimoda, Kazuya
University of Miyazaki
|
| ja |
下田, 和哉
宮崎大学
|
| ja-Kana |
シモダ, カズヤ
|
Search repository
Komatsu, Norio
Matsumura, Itaru
Ikeda, Kazuhiko
Hino, Masayuki
Hidaka, Michihiro
Maeda, Yoshinobu
Kondo, Takeshi
Fujisaki, Tomoaki
Shoshi, Keita
Azuma, Kyoichi
Fukushima, Ryuichi
Kawashima, Jun
Kosugi, Hiroshi
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Momelotinib, an oral Janus kinase (JAK) 1/2 and activin A receptor type 1 inhibitor, improved symptoms, splenomegaly, and anemia in patients with myelofibrosis (MF). This sub-analysis of SIMPLIFY-1 evaluated the efficacy and safety of momelotinib versus ruxolitinib in Japanese patients with JAK inhibitor (JAKi)-naïve MF. Patients were randomized 1:1 to receive momelotinib 200 mg once daily or ruxolitinib 20 mg twice daily (or modified based on label) for 24 weeks, after which patients could receive open-label momelotinib. The primary endpoint was splenic response rate (SRR; ≥ 35% reduction in spleen volume) at 24 weeks; main secondary endpoints were total symptom score (TSS) response (≥ 50% reduction) and transfusion independence (TI) rates. Fifteen Japanese patients (momelotinib, n = 6; ruxolitinib, n = 9) were enrolled; all completed treatment. At Week 24, SRR was 50.0% with momelotinib and 44.4% with ruxolitinib. TSS response rates were 33.3% and 0%, and TI rates were 83.3% and 44.4%. Any-grade treatment-related adverse event (TRAE) rates were 83.3% with momelotinib and 88.9% with ruxolitinib. Grade 3/4 TRAE rates were 0% and 55.6%, with specific events being anemia (55.6%) and vertigo (11.1%) with ruxolitinib. Momelotinib was well tolerated, improved spleen and symptom responses, and reduced transfusion requirements in Japanese patients with JAKi-naïve MF. |
|
言語 |
en |
| 内容記述 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
Citation: Kazuya Shimoda, Norio Komatsu, Itaru Matsumura, Kazuhiko Ikeda, Masayuki Hino, Michihiro Hidaka, Yoshinobu Maeda, Takeshi Kondo, Tomoaki Fujisaki, Keita Shoshi, Kyoichi Azuma, Ryuichi Fukushima, Jun Kawashima, Hiroshi Kosugi, Momelotinib versus ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis: an efficacy/safety analysis in the Japanese subgroup of the phase 3 randomized SIMPLIFY-1 trial, International Journal of Hematology, 120(3), 314-324, 2024-08-07, https://doi.org/10.1007/s12185-024-03822-z |
|
言語 |
en |
| bibliographic_information |
en : International Journal of Hematology
巻 120,
号 3,
p. 314-324,
発行日 2024-08-07
|
| 出版者 |
|
|
出版者 |
Springer Science and Business Media LLC |
|
言語 |
en |
| ISSN |
|
|
収録物識別子タイプ |
PISSN |
|
収録物識別子 |
0925-5710 |
| ISSN |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
1865-3774 |
| item_10001_relation_14 |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1007/s12185-024-03822-z |
| 権利 |
|
|
権利情報 |
© The Author(s) 2024 |
|
言語 |
en |
| 出版タイプ |
|
|
出版タイプ |
VoR |
article (842 KB)
.png)
